公开(公告)号：US20190225617A1

公开(公告)日：2019-07-25

申请号：US16258753

申请日：2019-01-28

Applicant: University Health Network

Inventor： Radoslaw Laufer ,  Grace Ng ,  Richard Brokx ,  Heinz W. Pauls ,  Sze-Wan Li ,  Jacqueline M. Mason ,  Mark R. Bray

IPC: C07D487/04 ,  A61P35/00 ,  A61P29/00 ,  A61K31/519 ,  A61K45/06 ,  A61P37/06

Abstract: The invention is a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).

公开(公告)号：US20190195896A1

公开(公告)日：2019-06-27

申请号：US16198965

申请日：2018-11-23

Applicant: University Health Network

Inventor： Avijit Chakrabartty ,  Rishi Rakhit ,  Anita Antoinette Bugyei-Twum

IPC: G01N33/78 ,  C07K16/26 ,  C07K14/47 ,  C07K16/18

CPC classification number: G01N33/78 ,  C07K14/47 ,  C07K14/575 ,  C07K16/18 ,  C07K16/26 ,  C07K2317/34 ,  C07K2317/76 ,  G01N33/74 ,  G01N2800/046 ,  G01N2800/28 ,  G01N2800/325 ,  G01N2800/7047

Abstract: The disclosure pertains to antibodies and binding fragments thereof that specifically binds all or part of EHAEVVFTA. Also provided are isolated peptides, isolated nucleic acids, immunogens, compositions, immunoassays and kits and method of using said reagents to detect misfolded TTR.

公开(公告)号：US20190183437A1

公开(公告)日：2019-06-20

申请号：US16227845

申请日：2018-12-20

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Edward TAYLOR ,  David A. JAFFRAY ,  Ivan Wai Tong YEUNG

IPC: A61B6/03 ,  G16H30/40 ,  A61B6/00 ,  A61B5/055 ,  G01T1/161 ,  A61K49/00

CPC classification number: A61B6/037 ,  A61B5/055 ,  A61B6/481 ,  A61B6/5235 ,  A61K49/0002 ,  G01T1/1611 ,  G01T1/2985 ,  G06T2207/30096 ,  G16H30/40

Abstract: Uptake of hypoxia-sensitive PET tracers is dependent on tissue transport properties, specifically, distribution volume. Variability in tissue transport properties reduces the sensitivity of static PET imaging to hypoxia. When tissue transport (vd) effects are substantial, correlations between the two methods of determining hypoxic fractions are greatly reduced—that is, trapping rates k3 are only modestly correlated with tumour-to-blood ratio (TBR). In other words, the usefulness of dynamic- and static-PET based hypoxia surrogates, trapping rate k3 and TBR, in determining hypoxic fractions is reduced in regions where diffusive equilibrium is achieved slowly. A process is provided for quantifying hypoxic fractions using a novel biomarker for hypoxia, hypoxia-sensitive tracer binding rate kb, based on PET imaging data. The same formalism can be applied to model the kinetics of non-binding CT and MT contrast agents, giving histopathological information about the imaged tissue.

公开(公告)号：US20190128885A1

公开(公告)日：2019-05-02

申请号：US16043782

申请日：2018-07-24

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Maria Cristina NOSTRO ,  Thomas KISLINGER ,  Kathryn COGGER ,  Ankit SINHA ,  Farida SARANGI

IPC: G01N33/566 ,  C12N5/071

Abstract: There is described herein a method for enriching/purifying a population of cells for pancreatic progenitor cells, the method comprising: a) providing the population cells, the population comprising pancreatic progenitor cells; and b) performing at least one of steps (i)-(v): (i) selecting for cells from the population that express at least one protein listed in cluster 2; (ii) selecting for cells from the population that express at least one protein listed in cluster 5; (iii) deselecting for cells from the population that express at least one protein listed in cluster 1; (iv) deselecting for cells from the population that express at least one protein listed in cluster 3; and (v) deselecting for cells from the population that express at least one protein listed in cluster 6.

公开(公告)号：US20190055608A1

公开(公告)日：2019-02-21

申请号：US16074635

申请日：2017-02-02

Applicant: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) ,  UNIVERSITY HEALTH NETWORK

Inventor： Paul Boutros ,  Robert G. Bristow ,  Sylvia Shiah ,  Michael Fraser ,  Veronica Sabelnykova ,  Vincent Huang ,  Lawrence Heisler ,  Takafumi Yamaguchi ,  Julie Livingstone

IPC: C12Q1/6886 ,  G06F19/20 ,  G06F19/18

Abstract: There is described herein a method of prognosing and/or predicting disease progression in subject with prostate cancer, the method comprising: a) providing a sample containing genetic material from cancer cells; b)determining or measuring at least 2 patient biomarkers regarding the prostate cancer tumor selected from the group consisting of: T category, ACTL6B methylation, TCERGL1 methylation, chr7:61 Mbp inter-chromosomal translocation, ATM single nucleotide variants and MYC copy number aberrations; c) comparing said patient biomarkers to corresponding reference or control biomarkers; and d) determining the likelihood of disease progression; wherein a likelihood of disease progression is higher with each of ACTL6B hyper-methylation, TCERGL1 hypo-methylation, higher T category, and higher incidences of chr7:61 Mbp inter-chromosomal translocation, ATM single nucleotide variants and MYC copy number aberrations, when the difference is statistically significant on comparison with the reference or control biomarkers.

公开(公告)号：US20190046540A1

公开(公告)日：2019-02-14

申请号：US16160403

申请日：2018-10-15

Applicant: University of Manitoba ,  University Health Network ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： Paul Fernyhough ,  Nigel A. Calcutt ,  Lakshmi Kotra

IPC: A61K31/5513 ,  C07D417/12 ,  A61K31/46 ,  A61K31/496

Abstract: Treatments for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof. The treatments includes administration of compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine, telenzepine, atropine, or derivatives thereof or salts thereof or analogs thereof or derivatives thereof, and a pharmacologically acceptable carrier. The composition may be injectable or alternatively, may be applied topically or alternatively, may be delivered orally. A suitable topical composition may comprise a lotion, a cream, a gel, or a viscous fluid. The muscarinic acetylcholine receptor antagonist may be a muscarinic acetylcholine receptor antagonist salt or a muscarinic acetylcholine receptor antagonist derivative or a muscarinic acetylcholine receptor antagonist analog.

公开(公告)号：US10194858B2

公开(公告)日：2019-02-05

申请号：US15450839

申请日：2017-03-06

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： César Marquez Chin ,  Kathryn Atwell ,  Milos R. Popovic

IPC: A61F2/72 ,  A61B5/00 ,  A61B5/0478 ,  A61N1/36 ,  A61B5/04 ,  A61B5/1468 ,  A61F5/01 ,  G06F3/01 ,  A61B5/048

Abstract: A method for characterizing a brain electrical signal comprising forming a temporo-spectral decomposition of the signal to form a plurality of time resolved frequency signal values, associating each instance of the signal value with a predetermined function approximating a neurological signal to form a table of coefficients collectively representative of the brain electrical signal.

公开(公告)号：US20190008885A1

公开(公告)日：2019-01-10

申请号：US16079405

申请日：2017-01-31

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Mohit KAPOOR ,  Akihiro NAKAMURA ,  Raja RAMPERSAUD

IPC: A61K31/7088 ,  A61P19/02 ,  G01N33/574

Abstract: There is disclosed herein methods, uses and systems for the detection, diagnosis, prognosis, treatment or prevention of a disease or condition comprising cartilage degeneration in a subject that is in need thereof. The methods comprise the use, inhibition or measurement of at least one of miR-181 a-5p and miR-4454, in the subject.

公开(公告)号：US20180271502A1

公开(公告)日：2018-09-27

申请号：US15762143

申请日：2016-09-22

Applicant: University Health Network

Inventor： Arash Zarrine-Afsar ,  David A. Jaffray ,  Alessandra Tata ,  Michael Woolman ,  Alexander Vitkin

IPC: A61B10/02 ,  H01J49/00 ,  H01J49/04 ,  A61B34/10 ,  A61B18/12 ,  A61B18/20 ,  A61B5/00 ,  A61B5/055 ,  A61B6/03 ,  A61B8/08

CPC classification number: A61B10/0266 ,  A61B5/0095 ,  A61B5/055 ,  A61B6/032 ,  A61B6/037 ,  A61B8/085 ,  A61B10/0233 ,  A61B18/12 ,  A61B18/20 ,  A61B34/10 ,  A61B2018/00577 ,  A61B2018/00595 ,  A61B2018/00904 ,  A61B2034/107 ,  A61B2034/2072 ,  G01N21/21 ,  H01J49/0004 ,  H01J49/0031 ,  H01J49/04

Abstract: Various embodiments are described herein for a system and a method for obtaining samples of tissue for analysis by mass spectrometry. A region of interest can be identified in tissue using image data from a first imaging modality that is other than mass spectrometry. At least one tissue sample can be acquired using a tissue sampler from a sampling location related to the region of interest. Mass spectrum data can be generated for the acquired tissue samples using a mass spectrometer. In some embodiments. polarimetry may be used on a tissue slice, mass spectrometry may be performed on the same tissue slice and then H&E imaging may be performed on the same tissue slice.

公开(公告)号：US10024844B2

公开(公告)日：2018-07-17

申请号：US14654139

申请日：2013-12-20

Applicant: Hospital for Special Surgery ,  University Health Network

Inventor： Carl Blobel ,  Thorsten Maretzky ,  David McIlwain ,  Tak Wah Mak

IPC: G01N33/48 ,  G01N33/50 ,  A61K39/395 ,  A61K45/06 ,  C07K16/18 ,  C12N15/113 ,  A61K39/00

Abstract: Disclosed are methods for treating a subject with an EGFR dependent pathology. The method comprises the step of administering to the subject an effective amount of an agent (“First Agent”) that decreases the biological activity of iRhom1 and an effective amount of an agent (“Second Agent”) that decreases the biological activity of iRhom2. Alternatively, the method comprises the step of administering to the subject an effective amount of an agent (“First Agent”) that modulates formation of a complex between iRhom 1 and TACE and an effective amount of an agent (“Second Agent”) that modulates formation of a complex between TACE and iRhom2. Also disclosed are assays for identifying such agents.